Leukemia
ALPINE trial, Zanubrutinib (2nd-gen BTKi) vs Ibrutinib (1st-gen BTKi)
In the randomized ALPINE trial, #Zanubrutinib (second-generation BTK inhibitor) improved the outcomes versus #ibrutinib (first-generation BTK inhibitor) in patients with...
RESONATE-2 trial
In the updated analysis of phase III RESONATE-2 trial, treatment with BTK inhibitor (#ibrutinib) for at least 5 years showed...
FDA approval of bevacizumab biosimilar
On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...
.png)